Clinic
First Choice Urgent Care PC
First Choice Urgent Care PC was paid $13.57M by Medicaid between Jan 2018 and Dec 2024, across 69 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 30% of everything it billed.
33Billing provider infoFIRST CHOICE URGENT CARE PC
DEARBORN, MI 48124
DEARBORN, MI 48124
33aNPI1629201264assigned 08/31/2009
33bProvider typeUrgent Care Clinic/Center
28Total paid$13.57M
24GClaims377,817
24DCodes billed69
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Michigan
Rank by total paid#2 of 239
Median peer was paid$346K
This provider vs. median39×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,491 | $542K | |
| 2019 | 15,836 | $592K | |
| 2020 | 30,845 | $953K | |
| 2021 | 105,587 | $3.71M | |
| 2022 | 68,770 | $2.38M | |
| 2023 | 75,113 | $2.76M | |
| 2024incomplete | 69,175 | $2.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 30% | 74,045 | 66,500 | $4.02M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 23% | 46,862 | 46,587 | $3.11M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 18% | 33,139 | 31,478 | $2.39M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 12% | 17,641 | 17,489 | $1.65M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 10% | 45,582 | 40,492 | $1.36M |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 342 | 342 | $126K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,419 | 10,259 | $121K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,580 | 2,321 | $106K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,454 | 10,726 | $91K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,907 | 6,772 | $82K |
| 99000 | <1% | 28,853 | 26,662 | $49K | |
| 99058 | <1% | 7,334 | 6,415 | $43K |
57 more codes
| 12001 | <1% | 778 | $40K | |
| 81025 | <1% | 9,288 | $39K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 89 | $36K |
| 81002 | <1% | 13,024 | $31K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 97 | $30K |
| 73130 | <1% | 1,573 | $30K | |
| 73620 | <1% | 1,290 | $20K | |
| 73600 | <1% | 989 | $17K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 174 | $16K |
| 69210 | <1% | 483 | $13K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 706 | $13K |
| 90715 | <1% | 440 | $12K | |
| 86328 | <1% | 333 | $12K | |
| 73110 | <1% | 361 | $9K | |
| 29125 | <1% | 255 | $9K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,789 | $8K |
| 10060 | <1% | 115 | $8K | |
| 93000 | <1% | 867 | $7K | |
| 73562 | <1% | 294 | $7K | |
| 87807 | <1% | 764 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 537 | $7K |
| 0001A | <1% | 183 | $6K | |
| 29130 | <1% | 263 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,605 | $5K |
| 0002A | <1% | 124 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 793 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,625 | $4K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 242 | $4K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 26 | $3K |
| 73030 | <1% | 140 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 64 | $2K |
| 99442 | <1% | 42 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 37 | $2K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 36 | $2K |
| 0011A | <1% | 52 | $2K | |
| 82962 | <1% | 513 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,834 | $1K |
| 73070 | <1% | 57 | $1K | |
| 0012A | <1% | 24 | $920.55 | |
| 73630 | <1% | 83 | $876.64 | |
| S9083 | Global fee urgent care centers | <1% | 2,731 | $807.50 |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 29 | $608.19 |
| 99001 | <1% | 260 | $600.00 | |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 12 | $592.38 |
| Q4049 | Finger splint, static | <1% | 301 | $387.88 |
| 29515 | <1% | 39 | $369.54 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 507 | $275.06 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 15 | $269.10 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 683 | $142.71 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 116 | $118.93 |
| 99072 | <1% | 32,540 | $108.57 | |
| 73610 | <1% | 14 | $89.98 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 379 | $22.09 |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 2,688 | $10.50 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 25 | $0.62 |
| 91300 | 0% | 46 | $0.00 | |
| S0630 | Removal of sutures; by a physician other than the physician who originally closed the wound | 0% | 285 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHASSAN, ALI (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Integrated Counseling Services, INC | Saint Cloud, MN | $24K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.